Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Celcuity announced REVTORPYK is now commercially available in the U.S. for eligible HR+/HER2- advanced breast cancer patients without a PIK3CA mutation.Key Highlights:Original SEC Filing: Celcuity Inc. [ CELC ] - 8-K - Sep. 30, 2026This is an AI-powered summary. It may contain inaccuracies. Conside…
Celcuity said REVTORPYK (gedatolisib) is now commercially available in the U.S. for HR+/HER2- advanced breast cancer without a PIK3CA mutation, in combo with fulvestrant with or without palbociclib, following progression after at least one metastatic endocrine therapy.Material DetailsContext by AI…